Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 13/20 | 0.36 |
| ▸ | F13A1 | P00488 | 11/20 | 0.36 |
| ▸ | TGM1 | P22735 | 8/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.35 |
| ▸ | KRAS | P01116 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 2/20 | 0.34 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1725753 | 0.92 | MAPT (0.35) | MAPTKDM4EHSD17B10 | |
| SCHEMBL2394029 | 0.87 | TGM2 (0.36) | TGM2F13A1TGM1MAPTTGM3 | |
| SCHEMBL2394669 | 0.84 | MAPT (0.33) | MAPTKRAS | |
| SCHEMBL12259618 | 0.82 | FPR2 (0.41) | TGM2F13A1TGM1MAPTTGM3 | |
| SCHEMBL12259616 | 0.80 | RAB9A (0.37) | MAPT | |
| SCHEMBL12259614 | 0.80 | BRD4 (0.43) | MAPTKRAS | |
| SCHEMBL12259615 | 0.80 | BRD4 (0.43) | MAPTKRAS | |
| SCHEMBL2394437 | 0.80 | KRAS (0.37) | MAPTKRASKDM4EBACE1 | |
| SCHEMBL2395926 | 0.79 | MAPK14 (0.39) | — | |
| SCHEMBL2392828 | 0.78 | MAPT (0.33) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012980-B2 | Isoquinolinone derivatives | ASTRAZENECA AB (SE) | 2011-09-06 | — | — | US | disclosed |
| US-20100099665-A1 | ISOQUINOLINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099665-A1 | ISOQUINOLINONE DERIVATIVES | SDHA, NQO1, CYP3A5 | TGM2 1801/4885F13A1 3933/4885TGM1 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.